Session (CTI)

In many low- and middle-income countries (LMICs), where a majority of patients pay out-of-pocket, traditional HEOR frameworks don’t always reflect real patient affordability and market realities. As disease burdens shift toward noncommunicable diseases (NCDs) and therapies become more specialized, reimbursement delays and limited public budgets widen the gap between innovation and access. In these environments, patients rely heavily on private insurance or personal funds, underscoring the need for access strategies tailored to LMIC-specific constraints not just adapted from high-income markets. This session is designed to bridge that gap by providing experience-based insights directly from LMIC settings. The session will explore practical, data-driven approaches for strengthening market access strategies in LMICs. Economist Panos Kanavos will open with an overview of how the market access and value assessment environment has evolved in LMICs. (10 min) Saba will introduce innovative tools and predictive models for segmenting patient affordability and creating sustainable access strategies in out-of-pocket markets – showing how these methods can complement and strengthen conventional HEOR assessments. (10 min) Oestergaard will outline real-world HTA challenges in LMICs, including the evolving role of differential pricing, and pragmatic approaches for improving value assessment in resource-constrained settings. (10 min) Masseria will provide the industry perspective, sharing lessons on navigating the payer landscape in LMICs. (10 min) Audience participation will focus on a real LMIC oncology case study. Working through key strategic questions with the guidance of our panelists, participants will practice applying the tools and frameworks introduced in the session. (20 min) This session blends expert insights with hands-on application to give attendees practical tools and actionable steps they can immediately apply to access strategy in LMICs.